Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ignis Acquires China Rights for ADHD Therapy Device from NeuroSigma

publication date: Jan 26, 2022

Ignis Therapeutics, a Shanghai CNS company, acquired China rights from NeuroSigma of Los Angeles to a device that treats attention deficit hyperactivity disorder (ADHD). The Monarch eTNS System is based on external trigeminal nerve stimulation (eTNS). In the US, the device is approved for use in children with ADHD aged 7 to 12. NeuroSigma believes it may also be an effective treatment for depression and epilepsy. In 2021, Ignis was formed by South Korea's SK Biopharma to bring SK's CNS drug assets to China. It raised $180 million in an A round led by 6 Dimensions. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital